Lilly Evista Breast Cancer Prevention Claims Promote Unapproved Use - FDA
Executive Summary
A Lilly press release promoting Evista's efficacy in breast cancer risk reduction constitutes promotion of an unapproved new use and must be halted, FDA declared in a Dec. 23 letter to the company.
You may also be interested in...
3M Qvar CFC-Free Beclomethasone Inhaler Will Be Launched In October
3M plans to launch its CFC-free beclomethasone metered-dose inhaler Qvar Oct. 23.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011